Efficacy

Introduction to Tagrisso (Osimertinib)

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) specifically designed for the treatment of certain types of non-small cell lung cancer (NSCLC). It is particularly effective in patients with tumors that have EGFR T790M mutation, which is a common resistance mechanism to earlier generation EGFR inhibitors. Osimertinib has shown a significant improvement in progression-free survival (PFS) compared to standard first-line treatments in patients with NSCLC harboring EGFR mutations.

Efficacy of Tagrisso in Clinical Trials

Clinical trials have demonstrated the efficacy of Tagrisso in treating NSCLC. The FLAURA study, a pivotal phase III clinical trial, compared osimertinib to standard EGFR-TKIs (erlotinib or gefitinib) in the first-line treatment of patients with NSCLC with EGFR mutations. The results showed that osimertinib significantly prolonged PFS, with a median of 18.9 months compared to 10.2 months in the control group. Moreover, Tagrisso was associated with a higher objective response rate (ORR) and a longer duration of response (DoR).

Introduction to Alunbrig (Brigatinib)

Alunbrig (brigatinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of ALK-positive NSCLC. It was designed to overcome resistance to crizotinib, the first-generation ALK inhibitor. Brigatinib has been shown to be effective in patients who have progressed on crizotinib and is also being evaluated as a first-line treatment. It has demonstrated high efficacy in terms of PFS and ORR in patients with ALK-positive NSCLC.

Efficacy of Alunbrig in Clinical Trials

The efficacy of Alunbrig was highlighted in the ALTA-1L trial, which is a phase III study comparing brigatinib to crizotinib in ALK-positive NSCLC patients who had not received prior ALK inhibitor therapy. The trial results indicated that brigatinib significantly improved PFS compared to crizotinib. Additionally, brigatinib showed a higher intracranial ORR in patients with brain metastases, which is a common complication in ALK-positive NSCLC. This suggests that brigatinib may be particularly beneficial for patients with CNS involvement.